当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Obesity and subcutaneous fat patterning in relation to survival of postmenopausal breast cancer patients participating in the DOM-project.

Obesity and subcutaneous fat patterning in relation to survival of postmenopausal breast cancer patients participating in the DOM-project.

Abstract：

:The effect of obesity and fat distribution on survival of breast cancer patients was studied prospectively in 241 women with a natural menopause who participated in a breast cancer screening project, the DOM-project in Utrecht, The Netherlands. Mean follow-up time was 9.1 years and endpoint of interest was death from breast cancer. Fat distribution was assessed by contrasting groups of subscapular and triceps skinfold thickness. No significant differences in survival time between more obese (Quetelet's index > or = 26 kg/m2) and leaner (Quetelet's index < 26 kg/m2) patients or between patients with central fat distribution and patients with peripheral fat distribution were observed. Analyses were stratified by axillary node status, estrogen receptor status, and way of detection (by first screening or afterwards). Results of the stratified analyses were suggestive of a modifying effect of these factors. The absence of an association between obesity and survival time might be explained by two counteracting mechanisms. On the one hand obesity might be related to impaired survival, due to a tumor growth promoting effect of extra-ovarian estrogens. On the other hand obesity might be related to improved survival in a screened population, because obese patients profit more from screening by earlier detection of tumors than leaner counterparts.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

den Tonkelaar I,de Waard F,Seidell JC,Fracheboud J

doi

10.1007/BF00665785

subject

Has Abstract

pub_date

1995-05-01 00:00:00

pages

129-37

issue

2

eissn

0167-6806

issn

1573-7217

journal_volume

34

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.

    abstract：:Evaluation of cost-utility is critical in assessing the medical utility of predictive or prognostic biomarkers. Current methods involve complex state-transition models, requiring comprehensive data inputs. We propose a simplified decision-analytic tool to explore the relative effect of factors contributing to the cost...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3677-3

    authors： Safonov A,Wang S,Gross CP,Agarwal D,Bianchini G,Pusztai L,Hatzis C

    更新日期：2016-01-01 00:00:00

  • Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.

    abstract：:The clinical benefit of eribulin versus capecitabine was evaluated using health-related quality of life (HRQoL) data from a phase 3 randomized trial in patients with pretreated advanced/metastatic breast cancer (ClinicalTrials.gov identifier: NCT00337103). The study population has been described previously (Kaufman et...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-015-3633-7

    authors： Cortes J,Hudgens S,Twelves C,Perez EA,Awada A,Yelle L,McCutcheon S,Kaufman PA,Forsythe A,Velikova G

    更新日期：2015-12-01 00:00:00

  • Sexual health in long-term breast cancer survivors.

    abstract：PURPOSE:Sexual dysfunction is reported in women with breast cancer (BC). It is unclear whether symptoms persist over time as data comparing long-term survivors to controls are lacking. We compared sexual functioning in long-term breast cancer survivors (BCS) to controls and determined the impact of adjuvant therapy on ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-4894-8

    authors： Soldera SV,Ennis M,Lohmann AE,Goodwin PJ

    更新日期：2018-11-01 00:00:00

  • Droloxifene, a new antiestrogen: its role in metastatic breast cancer.

    abstract：:Droloxifene, a new antiestrogen, has theoretical advantages over tamoxifen based on preclinical data. These include higher affinity to the estrogen receptor, higher antiestrogenic to estrogenic ratio, and more effective inhibition of cell growth and division in ER positive cell lines, as well as less toxicity, includi...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1007/BF00689679

    authors： Rauschning W,Pritchard KI

    更新日期：1994-01-01 00:00:00

  • Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration.

    abstract：:Sialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase: ST6GalNAc I, which catalyzes the transfer of a sialic acid residue in alpha2,6-linkage to the...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-3137-3

    authors： Julien S,Lagadec C,Krzewinski-Recchi MA,Courtand G,Le Bourhis X,Delannoy P

    更新日期：2005-03-01 00:00:00

  • Effects of anastrozole on lipid metabolism compared with tamoxifen in rats.

    abstract：BACKGROUND:Anastrozole, a new aromatase inhibitor, has been used to treat postmenopausal metastatic breast cancer, and several clinical trials of adjuvant treatment using this agent are ongoing. However, the effects of anastrozole on lipid metabolism are unknown. The aim of this study was to evaluate the effect of anas...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1020571617274

    authors： Hozumi Y,Hakamata Y,Sasanuma H,Ogura S,Nagai H

    更新日期：2002-11-01 00:00:00

  • Recurrence and survival rates in British and Japanese women with breast cancer.

    abstract：:The biology of breast cancer in Japan appears to be changing in that, while post-menopausal Japanese patients have a better prognosis than comparable British women, no differences in recurrence or survival rates can now be found in pre-menopausal patients. ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF02633545

    authors： Allen DS,Bulbrook RD,Chaudary MA,Hayward JL,Yoshida M,Miura S,Murai JT

    更新日期：1991-05-01 00:00:00

  • Pathology of borderline HER-2/neu breast carcinoma: a biologically distinct phenotype.

    abstract：PURPOSE:The significance of HER-2/neu results obtained by immunohistochemical analyses (IHC) which are neither negative nor strongly positive is controversial. The incidence of fluorescence in situ hybridization (FISH) positivity in these tumors is small and the implication is that these borderline results represent la...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-005-9136-1

    authors： Killeen JL,Ortega-Lopez A,Shaha J,Shaha SH,Fu JB

    更新日期：2006-07-01 00:00:00

  • Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.

    abstract：:Adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) have proven highly effective in rapidly proliferating breast cancer (RPBC). It has also been seen that sequential administration of doxorubicin and CMF is superior to their alternation, especially in indolent tumors. In a phase III study, we evaluated w...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-010-1257-5

    authors： Amadori D,Silvestrini R,De Lena M,Boccardo F,Rocca A,Scarpi E,Schittulli F,Brandi M,Maltoni R,Serra P,Ponzone R,Biglia N,Gianni L,Tienghi A,Valerio MR,Bonginelli P,Amaducci L,Faedi M,Baldini E,Paradiso A

    更新日期：2011-02-01 00:00:00

  • LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients.

    abstract：:Lysyl oxidase-like 2 (LOXL2) is associated with invasiveness and metastasis in breast cancer. We analyzed the prognostic impact of LOXL2 for breast cancer patients and investigated the role of LOXL2 in breast cancer cell lines. Immunohistochemical study of LOXL2 expression was done in samples from 309 patients. Surviv...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2662-3

    authors： Ahn SG,Dong SM,Oshima A,Kim WH,Lee HM,Lee SA,Kwon SH,Lee JH,Lee JM,Jeong J,Lee HD,Green JE

    更新日期：2013-08-01 00:00:00

  • Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.

    abstract：PURPOSE:The epithelial-mesenchymal transition (EMT) plays a key role in breast cancer progression and metastasis. Lipocalin 2 (LCN2) is involved in the regulation of EMT. The aim of this study was to investigate the clinicopathological significance of LCN2 expression in breast cancer. METHODS:The expression of LCN2 pr...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05488-2

    authors： Kurozumi S,Alsaeed S,Orah N,Miligy IM,Joseph C,Aljohani A,Toss MS,Fujii T,Shirabe K,Green AR,Aleskandarany MA,Rakha EA

    更新日期：2020-02-01 00:00:00

  • Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode.

    abstract：:Irreversible electroporation (IRE) is a therapeutic technology for the ablation of soft tissues using electrodes to deliver intense but short electric pulses across a cell membrane, creating nanopores that lead to cell death. This phenomenon only affects the cell membrane, leaving the extracellular matrix and sensitiv...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-0803-5

    authors： Neal RE 2nd,Singh R,Hatcher HC,Kock ND,Torti SV,Davalos RV

    更新日期：2010-08-01 00:00:00

  • Expression of pp32 gene family members in breast cancer.

    abstract：:The pp32 gene family consists of at least three closely related members, pp32, pp32r1 and pp32r2. In spite of a high degree of identity at the nucleotide level, pp32 functionally behaves as a tumor suppressor where as pp32r1 and pp32r2 are pro-oncogenic. The purpose of this pilot study was to determine pp32-related ex...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1017919507109

    authors： Kadkol SS,El Naga GA,Brody JR,Bai J,Gusev Y,Dooley WC,Pasternack GR

    更新日期：2001-07-01 00:00:00

  • Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.

    abstract：:Tamoxifen is currently the adjuvant treatment of choice for postmenopausal women with hormone-sensitive breast cancer. However, in the treatment of postmenopausal women with advanced disease, the third-generation aromatase inhibitor anastrozole ('Arimidex') has been shown to be at least as effective as tamoxifen, and ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1023/a:1025455130476

    authors： Aapro MS,Forbes JF

    更新日期：2003-01-01 00:00:00

  • Common genetic polymorphisms of microRNA biogenesis pathway genes and risk of breast cancer: a case-control study in Korea.

    abstract：:Recent compelling evidence indicates that mutation, aberrant expression, and dysregulation of microRNA (miRNA) biogenesis are implicated in cancer development and progression. Based on the important role of miRNA biogenesis pathway in carcinogenesis, we hypothesized that genetic variations in this pathway genes may pl...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1656-2

    authors： Sung H,Lee KM,Choi JY,Han S,Lee JY,Li L,Park SK,Yoo KY,Noh DY,Ahn SH,Kang D

    更新日期：2011-12-01 00:00:00

  • Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.

    abstract：PURPOSE:Fulvestrant is a selective estrogen receptor downregulator (SERD) that is approved for first- or second-line use as a single agent or in combination with cyclin dependent kinase or phosphatidylinositol 3-kinase inhibitors for the treatment of metastatic breast cancer. Fulvestrant exhibits exceptionally effectiv...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05454-y

    authors： Wardell SE,Yllanes AP,Chao CA,Bae Y,Andreano KJ,Desautels TK,Heetderks KA,Blitzer JT,Norris JD,McDonnell DP

    更新日期：2020-01-01 00:00:00

  • Factors associated with the incompliance with mammogram screening among individuals with a family history of breast cancer or ovarian cancer.

    abstract：OBJECTIVE:The national guidelines recommend more intensive screening for breast cancer for women with a family history of breast or ovarian cancer. Using the data from the 2000 National Health Interview Survey (NHIS), we examined factors related to the underuse of mammogram in this population. METHOD:The study subject...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9298-5

    authors： Wu H,Zhu K,Jatoi I,Shah M,Shriver CD,Potter J

    更新日期：2007-03-01 00:00:00

  • Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer.

    abstract：AIMS:Anthracyclines-taxanes containing regimens are widely used for breast cancer treatment both in neoadjuvant-adjuvant setting and in metastatic disease. Recently high-dose chemotherapy (HDC) with autologous stem cell support has been introduced as adjuvant treatment for high-risk primary breast cancer and for select...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1006462023110

    authors： Zambelli A,Robustelli della Cuna FS,Ponchio L,Ucci G,Da Prada GA,Robustelli della Cuna G

    更新日期：2000-06-01 00:00:00

  • Associations between mammographic density and serum and dietary cholesterol.

    abstract：:Although high mammographic density is a risk factor for postmenopausal breast cancer, its etiology remains unclear. We examined whether serum and dietary cholesterol, which increase breast cancer risk and are involved in endogenous estrogen formation, were associated with increased mammographic density. We conducted a...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-010-0927-7

    authors： Tamburrini AL,Woolcott CG,Boyd NF,Yaffe MJ,Terry T,Yasui Y,Jones CA,Patten SB,Courneya KS,Friedenreich CM

    更新日期：2011-01-01 00:00:00

  • Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study.

    abstract：:Obesity and metabolic syndrome are risk and prognostic factors for breast cancer (BC) and are associated with chronic inflammation. We investigated the association between distinct BC subtypes and markers of adiposity, dysmetabolisms, and inflammation. We analyzed 1779 patients with primary invasive BC treated at a si...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3802-3

    authors： Agresti R,Meneghini E,Baili P,Minicozzi P,Turco A,Cavallo I,Funaro F,Amash H,Berrino F,Tagliabue E,Sant M

    更新日期：2016-05-01 00:00:00

  • Tamoxifen-induced increases in cytoplasmic free Ca2+ levels in human breast cancer cells.

    abstract：:Tamoxifen has been shown to increase cytoplasmic free Ca2+ levels [Ca2+]i in renal tubular cells and bladder cancer cells, and to after Ca2+ signaling in MCF-7 breast cancer cells. The present study examined the effect of tamoxifen on [Ca2+], in ZR-75-1 human breast cancer cells using fura-2 as an indicator. Tamoxifen...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1013807731642

    authors： Chang HT,Huang JK,Wang JL,Cheng JS,Lee KC,Lo YK,Liu CP,Chou KJ,Chen WC,Su W,Law YP,Jan CR

    更新日期：2002-01-01 00:00:00

  • Tumor markers and their significance in the management of breast cancer. Workshop, National Institutes of Health, March 6, 1985.

    abstract：:The use of molecular components from both normal and neoplastic breast tissue as markers for breast tumors has long been recognized as of major potential for breast cancer diagnosis, and has been an area of active research. Recent developments in immunological approaches have further stimulated this field by permittin...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806776

    authors： Ceriani R,Anderson EP

    更新日期：1985-01-01 00:00:00

  • Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer.

    abstract：:Paclitaxel and vinorelbine are among the most active new agents in metastatic breast cancer. Both in vitro and in vivo studies have shown that the combined administration of these two microtubule-targeting agents is feasible and worthwhile. Based on the promising preclinical data, patients with metastatic breast cance...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1005848921895

    authors： Tortoriello A,Facchini G,Caponigro F,Santangelo M,Benassai G,Persico G,Citarella A,Carola M,Marzano N,Iaffaioli RV

    更新日期：1998-01-01 00:00:00

  • Pharmacology of aminoglutethimide: structure/activity relationships and receptor interactions.

    abstract：:The structure/activity relationships for inhibition of aromatase and cholesterol side-chain cleavage enzyme (CSCC) by aminoglutethimide and some of its analogues are reviewed. Although more effective against aromatase than CSCC, aminoglutethimide markedly inhibits both enzymes. Optimal competitive antagonism of aromat...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：

    authors： Nicholls PJ,Daly MJ,Smith HJ

    更新日期：1986-01-01 00:00:00

  • EpCAM expression is an indicator of recurrence in basal-like breast cancer.

    abstract：:Advances in the understanding of the molecular basis of breast cancer have necessitated a definition of more sensitive and specific indicators of prognosis that are central to the underlying cancer biology and that reflect the complicated and heterogeneous nature of the disease. This study investigates the expression ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1813-7

    authors： Agboola AJ,Paish EC,Rakha EA,Powe DG,Macmillan RD,Ellis IO,Green AR

    更新日期：2012-06-01 00:00:00

  • Smoking and survival after breast cancer diagnosis: a prospective observational study and systematic review.

    abstract：:The association of smoking with outcomes following breast cancer prognosis is not well understood. In a cohort study called Life After Cancer Epidemiology (LACE), 2,265 women diagnosed with breast cancer were followed for a median of 12 years. We used multivariable proportional-hazards models to determine whether smok...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-012-2276-1

    authors： Braithwaite D,Izano M,Moore DH,Kwan ML,Tammemagi MC,Hiatt RA,Kerlikowske K,Kroenke CH,Sweeney C,Habel L,Castillo A,Weltzien E,Caan B

    更新日期：2012-11-01 00:00:00

  • Height, weight, and risk of breast cancer relapse.

    abstract：:The records of 231 patients with primary breast cancer and 85 patients with metastatic breast cancer were reviewed to determine whether indices of body weight were associated with prognosis. Results support previous reports that indices of body weight are relatively weak, but real, prognostic factors. ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01807654

    authors： Eberlein T,Simon R,Fisher S,Lippman ME

    更新日期：1985-01-01 00:00:00

  • Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.

    abstract：PURPOSE:CIPN is a common, debilitating, and dose-limiting side effect of chemotherapy. Here, we describe characteristics of patients with CIPN using both patient-reported outcomes (PRO) and quantitative sensory testing (QST). METHODS:Breast cancer survivors with persistent moderate to severe CIPN defined by a rating o...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05416-4

    authors： Zhi WI,Chen P,Kwon A,Chen C,Harte SE,Piulson L,Li S,Patil S,Mao JJ,Bao T

    更新日期：2019-12-01 00:00:00

  • Utilization of hypofractionated whole-breast radiation therapy in patients receiving chemotherapy: a National Cancer Database analysis.

    abstract：PURPOSE:Results from four major hypofractionated whole-breast radiotherapy (HF-WBRT) trials have demonstrated equivalence in select patients with early-stage breast cancer when compared with conventionally fractionated WBRT (CF-WBRT). Because relatively little data were available on patients receiving neoadjuvant or ad...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4345-y

    authors： Diwanji TP,Molitoris JK,Chhabra AM,Snider JW,Bentzen SM,Tkaczuk KH,Rosenblatt PY,Kesmodel SB,Bellavance EC,Cohen RJ,Cheston SB,Nichols EM,Feigenberg SJ

    更新日期：2017-09-01 00:00:00

  • Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer.

    abstract：:The aim of this study is to identify and validate copy number aberrations in early-stage primary breast tumors associated with bone or non-bone metastasis. Whole-genome molecular inversion probe arrays were used to evaluate copy number imbalances (CNIs) in breast tumors from 960 early-stage patients with information a...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2796-3

    authors： Liu Y,Zhou R,Baumbusch LO,Tsavachidis S,Brewster AM,Do KA,Sahin A,Hortobagyi GN,Taube JH,Mani SA,Aarøe J,Wärnberg F,Børresen-Dale AL,Mills GB,Thompson PA,Bondy ML

    更新日期：2014-01-01 00:00:00